

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 31/47, 9/20</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/16442</b> <b>(43) International Publication Date:</b> 8 April 1999 (08.04.99)
<b>(21) International Application Number:</b> PCT/US98/17992 <b>(22) International Filing Date:</b> 3 September 1998 (03.09.98) <b>(30) Priority Data:</b> 60/060,827 30 September 1997 (30.09.97) US <b>(71) Applicant (for all designated States except US):</b> PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> JU, Tzu-chi, Robert [-/US]; 6152 Sablewood Circle, Portage, MI 49024 (US). <b>(74) Agent:</b> STEIN, Bruce; Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> SUSTAINED RELEASE TABLET FORMULATION TO TREAT PARKINSON DISEASE  <b>(57) Abstract</b>  The sustained release tablet of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) which is disclosed permits twice daily administration of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) to treat humans with Parkinson's disease.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SUSTAINED RELEASE TABLET FORMULATION  
TO TREAT PARKINSON DISEASE  
BACKGROUND OF THE INVENTION

1. Field of the Invention

5       The present invention is a pharmaceutical tablet formulation of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) and a method of using it to treat Parkinson's disease.

2. Description of the Related Art

10       US Patent 5,273,975 generically claims (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1), but does not disclosed it. It generically discloses that compounds are useful for treating Parkinson's disease.

15       US Patent 4,389,393 claims a sustained release pharmaceutical tablet formulation with less than 25.8% hydroxypropyl methylcellulose. Hydroxypropyl methylcellulose has been used extensively for producing sustained release (slow disintegration) tablet formulations.

      US Patent 5,000,962 discloses a long acting tablet formulation which comprises more than 35 to 60% (by weight) of hydroxypropyl methylcellulose and lactose was used as an excipient. The present invention uses no lactose.

20       Dow's 1995 Formulating for Controlled Release With Methocel Premium Cellulose Ethers in Figure 24 on page 21 discloses the use of starch with Methocel (hydroxypropyl methocellulose) for producing tablets containing theophylline. The tablets of the present invention do not contain theophylline but rather (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1). Figure 20 on page 20 discloses a relationship between tablet size and the percent released with lactose. Normally starch is used in an amount up to about 15-20% for immediate release tablet formulations. However, in sustained release formulations it is not used because it is preceived to promote disintergation. Dow discloses the use of starch (excipient) at an amount of 52.6%. The tablet formulation of the present invention uses starch in an amount of more than 60%.

30       International Publication WO97/34932 discloses pharmaceutical tablets containing mechanically damaged starch which provide delayed, controlled and targeted release formulations. The present invention does not use mechanically damaged starch.

35       International Publication WO97/37639 discloses a controlled-release pharmaceutical tablet containing cross-linked amylose and hydroxypropylmethylcellulose and 10-30% of hydroxypropyl methylcellulose. The

tablet formulation of the presnet invention uses no cross-linked amylose and has from 30-40% hydroxypropyl methylcellulose.

### SUMMARY OF INVENTION

Disclosed is a pharmaceutical composition which is a sustained release tablet  
5 for oral ingestion which comprises:

- |  |            |
|--|------------|
| (a) (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-<br>quinolin-2(1H)-one (Z)-2-butenedioate (1:1) | 0.3% - 16% |
| (b) starch   | 60% - 69%  |
| (c) hydroxypropyl methylcellulose  | 30% - 40%  |

10 Further disclosed is a method of treating humans who have Parkinson's disease which comprises orally administering an anti-Parkinson's effective amount of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1).

### DETAILED DESCRIPTION OF THE INVENTION

15 (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) is made according to the process set forth in CHART A and in EXAMPLEs 1 thru 8.

It is preferred that (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) be administered as a capsule or tablet,  
20 more preferably a tablet. The tablet formulation contains the following components, the pharmacologically active ingredient, starch and hydroxypropyl methylcellulose.

The amount of the active ingredient, (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1), per tablet is from about 0.3% (1 mg) to about 16% (56 mg) of (R)-5,6-dihydro-5-(methylamino)-4H-  
25 imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1); preferably from about 0.44% (1.5 mg) to about 10% (35 mg) of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1)/tablet. Note that 1 mg of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate salt is equivalent to about 0.63 mg of the free base, (R)-5,6-dihydro-5-  
30 (methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one. It is preferred that the tablet be about 350 mg in total weight.

Many different starches are useful and can be used in place of each other or in combination with each other as mixtures. They include potato, corn, wheat, pregelatinized, sodium starch glycolate and equivalents thereof. It is preferred that  
35 the starch be either corn or pregelatinized starch, or a mixture thereof. The starch should be present in an amount of from about 60 to about 69%.

The hydroxypropyl methylcellulose should be present in an amount of from about 30 to about 40%. It is preferred that the hydroxypropyl methylcellulose be selected from the group consisting of hydroxypropyl methylcellulose 2208 USP 100 cps, hydroxypropyl methylcellulose 2208 USP 4,000 cps, hydroxypropyl methylcellulose 2208 USP 15,000 cps, hydroxypropyl methylcellulose 2208 USP 100,000 cps, hydroxypropyl methylcellulose 2910 USP 4,000 cps, hydroxypropyl methylcellulose 2910 USP 10,000 cps, or mixtures thereof. It is preferred that the hydroxypropyl methylcellulose be hydroxypropyl methylcellulose 2208 USP 4,000 cps or hydroxypropyl methylcellulose 2910 USP 4,000 cps. The hydroxypropyl methylcellulose can be any of the hydroxypropyl methylcelluloses individually or mixtures thereof.

It is preferable that the tablets contain magnesium stearate but it is not required. If magnesium stearate is present, it should be in an amount of from about 0.2 to about 2.0 %.

It is preferable that the tablets contain colloidal silicon dioxide but it is not required. If colloidal silicon dioxide is present, it should be in an amount of from about 0.2 to about 1.0 %.

As is known to those skilled in the art, other agents such as sweeteners, coloring agents, coatings, etc can be added to the tablet.

The tablet is made by either direct compression or wet granulation, both processes are well known to those skilled in the art. If the direct compression method is used, the active ingredient (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1), the starch and the hydroxypropyl methylcellulose (and colloidal silicon dioxide, if used) are first individually screened and then mixed in an appropriate size container or blender. If magnesium stearate is used it also is screened and mixed with a portion of the material from the container or blender and then all the materials are thoroughly mixed. This lubricated mixture is compressed into tablets of desired weight and physical specifications by methods known to those skilled in the art.

If the wet granulation method is used, a binder solution is prepared using hydroxypropyl cellulose or povidone (PVP). The binder solution is sprayed into a mixture of the pharmaceutically active ingredient, (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) and a portion of the other ingredients except the lubricant (magnesium stearate). The wet granules should be dried in a dryer such as a fluidized bed. The dry mixture should then be mixed with the lubricant and the remaining ingredients to form the final mixture

which is compressed into tablets of desired weight and physical specifications by methods known to those skilled in the art.

(R)-5,6-Dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) is used in the treatment of Parkinson's disease. It is administered twice a daily orally in the form of a tablet or capsule, preferably a tablet. Since Parkinson's disease is disease of the elderly and children are not involved, the drug is not expressed as mg/kg but rather as the amount per day. It is preferred that (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) be given in an amount of about 2 mg to about 112 mg/day, more preferably from about 3 mg to about 70 mg/day. It is preferred that the daily dose be divided into two equal amounts since the sustained release tablet formulation adequately maintains blood levels when administered twice daily.

The exact dosage and frequency of administration depends the severity of the condition being treated, the weight, general physical condition of the particular patient, other medication the individual may be taking as is well known to those skilled in the art and can be more accurately determined by measuring the blood level or concentration of the free base of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) in the patient's blood and/or the patient's response to the particular condition being treated.

## DEFINITIONS AND CONVENTIONS

The definitions and explanations below are for the terms as used throughout this entire document including both the specification and the claims.

### DEFINITIONS

All temperatures are in degrees Centigrade.

TLC refers to thin-layer chromatography.

HPLC refers to high pressure liquid chromatography.

Saline refers to an aqueous saturated sodium chloride solution.

Chromatography (column and flash chromatography) refers to purification/separation of compounds expressed as (support; eluent). It is understood that the appropriate fractions are pooled and concentrated to give the desired compound(s).

IR refers to infrared spectroscopy.

NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical shifts are reported in ppm ( $\delta$ ) downfield from tetramethylsilane.

$[\alpha]_D^{25}$  refers to the angle of rotation of plane polarized light (specific optical rotation) at 25° with the sodium D line (589A).

MS refers to mass spectrometry expressed as m/e, m/z or mass/charge unit. [M + H]<sup>+</sup> refers to the positive ion of a parent plus a hydrogen atom. EI refers to electron impact. CI refers to chemical ionization. FAB refers to fast atom bombardment.

5 Ether refers to diethylether.

Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and  
10 bioavailability.

When solvent pairs are used, the ratios of solvents used are volume/volume (v/v).

When the solubility of a solid in a solvent is used the ratio of the solid to the solvent is weight/volume (wt/v).

15 All reactions are run under a nitrogen atmosphere.

Melting points are uncorrected.

GLC conditions are as follows: Hewlett-Packard Model 5890A capillary gas chromatograph, J & W Scientific Inc., DB-5.5% phenylmethyl silicone column (15 m x 0.53 mm x 1.5 µm film thickness), helium carrier gas (100 ml/min.), hydrogen  
20 flame ionization detector. Programmed: 100°, 1 min; increasing 20°/min to 250°; 250°, 10 min.

HPLC conditions are as follows: Zorbax Rx-C8 column (4.6 mm x 25 cm), solvent A - 10% acetonitrile and 90% water (pH = 3 phosphate buffer), solvent B - 85% acetonitrile and 15% water (pH 3 = phosphate buffer), programmed gradient:  
25 90% A/10% B to 5% A/95% B over 12 minutes, maintain at 5% A/95% B for 4 to 10 minutes; λ = 215 nm, flow = 2 ml/min.

USP refers to United States Pharmacopeia.

cps refers to centiposes.

### EXAMPLES

30 Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way  
35 whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and

techniques.

EXAMPLE 1 (R)-2-(Methoxycarbonylamino)-3-phenylpropanoic acid (II)

A mixture of D-phenylalanine (I, 25.00 g, 0.151 mol) and sodium hydroxide (6.05 g, 0.151 mol) in water (170 ml) and tetrahydrofuran (225 ml) is cooled to -15°, and a mixture of methyl chloroformate (18.6 g, 0.197 mol) in tetrahydrofuran (50 ml) is added dropwise. When the one-half of the methyl chloroformate had been added, a mixture of sodium hydroxide (9.10 g, 0.227 mol) in water (20 ml) is added. When the addition is complete, the mixture is stirred at 25° for an additional 2 hours and acidified with hydrochloric acid (10%) to pH 2. The mixture is extracted twice with ether and the extracts are washed with saline and dried over magnesium sulfate. The solvent is removed under reduced pressure to give the title compound, NMR (CDCl<sub>3</sub>) 3.09, 3.19, 3.65, 4.66, 5.25, 7.15-7.31 and 8.22 δ; IR (thin film) 1726, 1498, 1455, 1448 and 1377 cm<sup>-1</sup>; MS calculated for C<sub>11</sub>H<sub>13</sub>NO<sub>4</sub> = 224.0923, found = 224.0921.

EXAMPLE 2 (R)-N-Methoxy-2-(methoxycarbonylamino)-3-phenylpropanamide (III)

A mixture of sodium carbonate (10.20 g, 96.2 mmol) in water (170 ml) is added to a mixture of (R)-2-(methoxycarbonylamino)-3-phenylpropanoic acid (II, EXAMPLE 1, ~0.148 mol crude) in methylene chloride. Methoxylamine hydrochloride (14.2 g, 0.170 mol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (31.21 g, 0.163 mol) are added, and the mixture is stirred at 20-25° for 22 hours. The mixture is diluted with tetrahydrofuran (to dissolve the precipitate) and the layers are separated. The aqueous layer is extracted with 1:1 tetrahydrofuran/ether, and the combined organic extracts are washed with hydrochloric acid (10%) and saturated sodium bicarbonate solution. The mixture is dried over magnesium sulfate, filtered and the solvent removed under reduced pressure. Crystallization from ethyl acetate gives the title compound, mp = 154-155°; NMR (CDCl<sub>3</sub>) 3.05, 3.58, 3.61, 4.34, 5.66, 7.15-7.31 and 9.44 δ; IR (mineral oil) 1694 and 1668 cm<sup>-1</sup>; [α]<sub>D</sub><sup>25</sup> = +5.2° (CH<sub>3</sub>OH, c = 1.045).

EXAMPLE 3 Methyl (R)-N-(1,2,3,4-Tetrahydro-1-methoxy-2-oxo-3-quinolinyl)-carbamate (IV)

A suspension of (R)-N-methoxy-2-(methoxycarbonylamino)-3-phenylpropanamide (III, EXAMPLE 2, 11.25 g, 44.6 mmol) in dichloromethane (170 ml) is cooled in an ice bath and trifluoroacetic acid (9.25 ml, 13.7 g, 0.120 mol) is added. Bis(trifluoroacetoxy)iodobenzene (19.78 g, 0.046 mol) is added portion wise over 10 min at 0°, and the mixture is stirred at this temperature for one hour. The



mixture is washed with sodium carbonate mixture (10%) and dried over magnesium sulfate. The solvent is removed under reduced pressure to give a concentrate.

Purification by flash chromatography (230-400 mesh silica gel, 40-50% ethyl acetate/hexane) gives the desired product. An analytical sample is crystallized from ethyl acetate/hexane to give the title compound, mp = 117-119°; NMR (CDCl<sub>3</sub>) 2.85, 3.44, 3.72, 3.93, 4.42, 5.82, 7.09, 7.33 and 7.22 δ; IR (mineral oil) 1722 and 1703 cm<sup>-1</sup>; [α]<sub>D</sub><sup>25</sup> = +34.2° (CH<sub>3</sub>OH, c = 0.927).

EXAMPLE 4 (R)-3-Methylamino-1,2,3,4-tetrahydroquinoline maleate (V)

A mixture of (R)-N-(1,2,3,4-tetrahydro-1-methoxy-2-oxo-3-quinoliny)l)carbamate (IV, EXAMPLE 3, 29.1 g, 116.4 mmol) in dry tetrahydrofuran (400 ml) is cooled to 0° and borane methylsulfide (10.0 M solution, 70 ml, 6.0 eq) is slowly added. The mixture is allowed to warm to 25° and stirred for 2.5 hours. The mixture is then refluxed on a steam bath for 30 hours and then cooled to 0°, quenching dropwise (careful - hydrogen evolution) with hydrochloric acid (10%, 160 ml). This mixture is refluxed on the steam bath for 1.5 hours, cooled in ice, and made basic with aqueous sodium hydroxide (12 N). The mixture is extracted twice with ether and the combined extracts are washed with saline and dried over magnesium sulfate. The solvent is removed under reduced pressure to a concentrate which is carried on without further purification. Examination of crude diamine (V) by GLC shows peaks at 5.15 min (2%), 5.46 min (V, 85%), 5.83 min (3%) and 7.39 min (10%). To obtain an analytical sample, an aliquot of crude (V) is crystallized as its maleate salt in methanol/ether, mp = 175°; NMR of the maleic acid salt (CDCl<sub>3</sub>) 2.64, 2.80, 3.11, 3.20-3.52, 3.55, 5.92, 6.03, 6.53-6.58, 6.927-6.97 and 8.48 δ; [α]<sub>D</sub><sup>25</sup> = +19.0° (CH<sub>3</sub>OH, c = 1.01); IR (thin film) 1638 and 1608 cm<sup>-1</sup>.

EXAMPLE 5 (R)-Methyl-(1,2,3,4-tetrahydro-3-quinoliny)l)carbamic acid, phenylmethyl ester (VI)

A mixture of (R)-1,2,3,4-tetrahydro-N-methyl-3-quinolinamine of crude material prepared above (V, EXAMPLE 4, 15.0 g), approximately 84.4 mmol) in toluene (50 ml) is stirred at -40° while N-(benzyloxycarbonyloxy)succinimide (24.2 g, 97.1 mmol) in toluene (150 ml) is added over one hr. After 30 min at -40°, GLC analysis indicated that all of (V) had been consumed. The mixture is quenched by the addition of sodium bicarbonate (10% aqueous solution, 300 ml) and warmed to 0°, followed by the addition of methanol (100 ml). This is stirred overnight and then extracted with ethyl acetate. Drying over magnesium sulfate and solvent removal gives a liquid which is purified by flash chromatography (230-400 mesh silica gel; hexane/ethyl acetate, 4/1) which crystallized from ethyl acetate/hexane to give the

title compound, mp = 80°; NMR (CDCl<sub>3</sub>) 2.88, 2.80-3.04, 3.30, 3.83, 4.57, 5.16, 6.51, 6.64, 6.96-7.02 and 7.35 δ; [α]<sup>25</sup><sub>D</sub> = -50.1° (CH<sub>3</sub>OH, c = 0.816); IR (mineral oil) 1680 and 1606 cm<sup>-1</sup>.

EXAMPLE 6 (R)-Methyl-[1,2,3,4-tetrahydro-1-[(methoxyamino)carbonyl]-3-quinolinyl]carbamic acid, phenylmethyl ester (VII)

A mixture of (R)-methyl-(1,2,3,4-tetrahydro-3-quinolinyl)carbamic acid, phenylmethyl ester (VI, EXAMPLE 5, 3.81 g, 12.86 mmol) and triethylamine (3.9 g, 39 mmol) in dry tetrahydrofuran (50 ml) is added with stirring to a mixture of phosgene (7.1 ml of a 1.93 M toluene solution) in tetrahydrofuran (100 ml) at 0°.

After one hour, methoxylamine hydrochloride (2.15 g, 25.7 mmol) and triethylamine (3.9 g, 39 mmol) are added, and the mixture is stirred at 20-25° for two days. The mixture is diluted with ether and washed with water and saline. The organic layer is dried over magnesium sulfate and the solvent is removed under reduced pressure. The residue is sufficiently pure for the next step. An analytical sample is purified via flash chromatography (230-400 mesh silica gel; ethyl acetate/hexane, 50/50) to give the title compound, NMR (CDCl<sub>3</sub>) 2.88, 2.77-2.97, 3.75, 3.52-4.08, 4.54, 5.13, 7.10-7.27, 7.35 and 7.76 δ; IR (thin film) 1734, 1697 and 1605 cm<sup>-1</sup>; [α]<sup>25</sup><sub>D</sub> = +38° (CH<sub>3</sub>OH, c = 0.980); MS calculated for C<sub>20</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub> = 369.1688, found = 369.1682.

EXAMPLE 7 (R)-Methyl-(1,2,5,6-tetrahydro-1-methoxy-2-oxo-4H-imidazo[4,5,1-ij]quinolinyl-5-yl)carbamic acid, phenylmethyl ester (VIII)

A mixture of (R)-methyl-[1,2,3,4-tetrahydro-1-[(methoxyamino)carbonyl]-3-quinolinyl]carbamic acid, phenylmethyl ester (VII, EXAMPLE 6, 7.26 g, 19.7 mmol) in chloroform (150 ml) is cooled to -5° in an ice-salt bath.

Bis(trifluoroacetoxy)iodobenzene (10.14 g, 23.6 mmol) is added, and the mixture is stirred at -5° to 0° for four hours and then at 20-25° for two more hours at which time the reaction is complete by TLC. The reaction mixture is washed with 10% aqueous sodium carbonate, back-extracting the aqueous fractions with ether. The combined organic layers are dried over magnesium sulfate, and the solvent removed under reduced pressure to a concentrate. Purification of the concentrate by flash chromatography (230-400 mesh silica gel; ethyl acetate/hexane, 50/50) gives the product. HPLC analysis indicated two peaks, 10.79 min (97.4%) and 11.95 min (2.6%). An analytical sample (0.54 g) is crystallized from ethyl acetate/hexane to give the title compound, mp = 105-106.5°; NMR (CDCl<sub>3</sub>) 2.93, 2.90-3.30, 3.14, 3.68, 4.07, 4.11, 4.65, 5.16, 6.88, 6.96, 7.04 and 7.36 δ; IR (mineral oil): 1725, 1717 and 1694 cm<sup>-1</sup>; [α]<sup>25</sup><sub>D</sub> = +46.8° (CH<sub>3</sub>OH, c = 0.731).

EXAMPLE 8 (R)-5,6-Dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one maleate (IX)

A mixture of methyl-(1,2,5,6-tetrahydro-1-methoxy-2-oxo-4H-imidazo[4,5,1-ij]quinolinyl-5-yl)carbamic acid phenylmethyl ester (VIII, EXAMPLE 7, 3.87 g, 10.5 mmol) and 20% palladium hydroxide on carbon (1.0 g) in absolute ethanol (100 ml) is shaken in a Parr apparatus with an initial hydrogen pressure of 50 psi for 19 hours. The mixture is filtered through diatomaceous earth, and the catalyst is washed with ethanol. and the solvent is removed under reduced pressure. The concentrate is dissolved in methanol (25 ml) and added to a mixture of maleic acid (1.20 g, 10.3 mmol) in methanol (25 ml). Crystallization gives the desired product, mp = 211°. A second crop is obtained by adding ether (0.29 g). HPLC analysis of the title compound indicates it to be greater than 99% pure; NMR of the maleic acid salt (DMSO) 2.68, 3.05, 3.22, 3.90-4.06, 6.05, 6.85-6.97, 8.74 and 10.83  $\delta$ ; IR (mineral oil) 1696 and 1638  $\text{cm}^{-1}$ ;  $[\alpha]_D^{25} = -26.3^\circ$  ( $\text{H}_2\text{O}$ ,  $c = 0.836$ ).

EXAMPLE 9 Tablet - 35% Hydroxypropyl Methylcellulose 2208 USP 4,000 cps - 350 mg Tablet

(R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-

quinolin-2(1H)-one (Z)-2-butenedioate (1:1) 3.97 mg (1.1%)

Pregelatinized Starch 220.38 mg (62.8%)

Hydroxypropyl Methylcellulose 2208 USP 4,000 cps 122.50 mg (35.0%)

Colloidal Silicon Dioxide 1.40 mg (0.4%)

Magnesium Stearate 1.75 mg (0.5%)

Total Tablet Weight 350.00 mg (100%)

The tablet is prepared by dry granulation as follows. The pharmaceutically active ingredient, (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1), the starch, the hydroxypropyl methylcellulose and the colloidal silicon dioxide are individually screened and then mixed in an appropriate size container or blender. The magnesium stearate is screened and mixed with a portion of the material from the container or blender and then all the materials are thoroughly mixed. This lubricated mixture is compressed into 350 mg tablets of desired physical specifications.

EXAMPLE 10 Tablet - 35% Hydroxypropyl Methylcellulose 2910 USP 4,000 cps - 350 mg Tablet

(R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-

quinolin-2(1H)-one (Z)-2-butenedioate (1:1) 3.97 mg

Pregelatinized Starch 220.38 mg

Hydroxypropyl Methylcellulose 2910 USP 4,000 cps	122.50 mg
Colloidal Silicon Dioxide	1.40 mg
Magnesium Stearate	1.75 mg
Total Tablet Weight	350.00 mg

- 5        Following the general procedure of EXAMPLE 9 and making non-critical variations the tablet formulation of EXAMPLE 10 is prepared.

EXAMPLE 11        Tablet - 35% Hydroxypropyl Methylcellulose 2910 USP 4,000 cps - 350 mg Tablet; Corn Starch

10        (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1)	3.97 mg
Corn Starch	220.38 mg
Hydroxypropyl Methylcellulose 2910 USP 4,000 cps	122.50 mg
Colloidal Silicon Dioxide	1.40 mg
Magnesium Stearate	1.75 mg
15        Total Tablet Weight	350.00 mg

          Following the general procedure of EXAMPLE 9 and making non-critical variations the tablet formulation of EXAMPLE 11 is prepared.









CHART A


CHART A - continued

5




(V)

10



(VI)

20



(VII)

30




35

CHART A - continued

5



10




(VIII)

15



20



(IX)

25

CLAIMS

1. A pharmaceutical composition which is a sustained release tablet for oral ingestion which comprises:
  - (a) (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) 0.3% - 16%
  - (b) starch 60% - 69%
  - (c) hydroxypropyl methylcellulose 30% - 40%
2. A pharmaceutical composition according to claim 1 which comprises:
  - (a) (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) 0.44% - 10%
  - (b) pregelatinized or corn starch 60% - 67%
  - (c) hydroxypropyl methylcellulose 30% - 40%
3. A pharmaceutical composition according to claim 1 where (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) is present in an amount from about 0.3% (1 mg) to about 16% (56 mg) /tablet.
4. A pharmaceutical composition according to claim 1 where (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) is present in an amount of about 0.44% (1.5 mg), 0.88% (3.1 mg), 1.76% (6.2 mg), 3.52% (12.3 mg) and 5.33% (19 mg) /tablet.
5. A pharmaceutical composition according to claim 1 where the starch is pregelatinized or corn starch.
6. A pharmaceutical composition according to claim 1 where the starch is a mixture of pregelatinized and corn starch.
7. A pharmaceutical composition according to claim 1 where the hydroxypropyl methylcellulose is selected from the group consisting of
  - hydroxypropyl methylcellulose 2208 USP 100 cps,
  - hydroxypropyl methylcellulose 2208 USP 4,000 cps,
  - hydroxypropyl methylcellulose 2208 USP 15,000 cps,
  - hydroxypropyl methylcellulose 2208 USP 100,000 cps,
  - hydroxypropyl methylcellulose 2910 USP 4,000 cps,



hydroxypropyl methylcellulose 2910 USP 10,000 cps,  
or mixtures thereof.

8. A pharmaceutical composition according to claim 7 where the hydroxypropyl  
5 methylcellulose is hydroxypropyl methylcellulose 2208 USP 4,000 cps or  
hydroxypropyl methylcellulose 2910 USP 4,000 cps.
9. A pharmaceutical composition according to claim 1 which contains magnesium  
stearate.
10. A pharmaceutical composition according to claim 9 where the magnesium  
stearate is present in an amount of from about 0.2 to about 2.0 %.
11. A pharmaceutical composition according to claim 1 which contains colloidal  
15 silicon dioxide.
12. A pharmaceutical composition according to claim 11 where the colloidal silicon  
dioxide is present in an amount of from about 0.2 to about 1.0 %.
13. A pharmaceutical composition according to claim 1 where the tablet is about  
20 350 mg in total weight.
14. A method of treating humans who have Parkinson's disease which comprises  
orally administering an anti-Parkinson's effective amount of (R)-5,6-dihydro-5-  
25 (methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1).
15. A method of treating humans who have Parkinson's disease according to claim  
14 where the (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one  
(Z)-2-butenedioate (1:1) is administered twice daily.
16. A method of treating humans who have Parkinson's disease according to claim  
14 where the effective amount is from about 2 mg to about 112 mg/day.
17. A method of treating humans who have Parkinson's disease according to claim  
35 16 where the effective amount is from about 3 mg to about 70 mg/day.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/47, 9/20</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/16442</b> <b>(43) International Publication Date:</b> 8 April 1999 (08.04.99)
<b>(21) International Application Number:</b> PCT/US98/17992 <b>(22) International Filing Date:</b> 3 September 1998 (03.09.98) <b>(30) Priority Data:</b> 60/060,827 30 September 1997 (30.09.97) US <b>(71) Applicant (for all designated States except US):</b> PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> JU, Tzu-chi, Robert [-/US]; 6152 Sablewood Circle, Portage, MI 49024 (US). <b>(74) Agent:</b> STEIN, Bruce; Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> <b>(88) Date of publication of the international search report:</b> 17 June 1999 (17.06.99)
<b>(54) Title:</b> SUSTAINED RELEASE TABLET FORMULATION TO TREAT PARKINSON DISEASE <b>(57) Abstract</b> <p>The sustained release tablet of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) which is disclosed permits twice daily administration of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) to treat humans with Parkinson's disease.</p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	BS	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/17992

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K31/47 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 126, no. 8, 24 February 1997 Columbus, Ohio, US; abstract no. 99157, XP002099549 see abstract & R.F.HEIER ET AL.: "SYNTHESIS AND BIOLOGICAL ACTIVITIES OF (R)-5,6-DIHYDRO-N,N-DIMETHYL-4H-IMIDAZO '4,5,1-ij! QUINOLIN-5-AMINE AND ITS METABOLITES." J. MED. CHEM., vol. 40, no. 5, 1997, pages 639-646, ---	1, 14
A	WO 90 15058 A (UPJOHN) 13 December 1990 cited in the application see claims 1,17 see page 13, line 22 - line 35 ---	1-17
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "3" document member of the same patent family

Date of the actual completion of the international search

13 April 1999

Date of mailing of the international search report

23/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

# INTERNATIONAL SEARCH REPORT

Intern. Appl. Application No

PCT/US 98/17992

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 389 393 A (J.M.SCHOR ET AL.) 21 June 1983 cited in the application see the whole document ---	1-17
A	WO 97 34932 A (BRITISH TECHNOLOGY) 25 September 1997 cited in the application see the whole document ---	1-17
A	US 5 000 962 A (S.SANGEKAR ET AL.) 19 March 1991 cited in the application see the whole document ---	1-17
A,P	WO 97 37639 A (LABOPHARM) 16 October 1997 cited in the application see the whole document -----	1-17

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/17992

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 14-17  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/17992

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9015058 A	13-12-1990	AT 117688 T	15-02-1995
		AU 626427 B	30-07-1992
		AU 5743890 A	07-01-1991
		CA 2051697 A,C	10-12-1990
		DE 69016430 D	09-03-1995
		DE 69016430 T	01-06-1995
		DK 480939 T	10-07-1995
		EP 0480939 A	22-04-1992
		ES 2067744 T	01-04-1995
		FI 96310 B	29-02-1996
		FI 944704 A,B,	07-10-1994
		HK 65397 A	23-05-1997
		HU 210264 B	28-03-1995
		HU 9500660 A	28-11-1995
		JP 4506071 T	22-10-1992
		NO 301421 B	27-10-1997
		RU 2023712 C	30-11-1994
		US 5436240 A	25-07-1995
		US 5273975 A	28-12-1993
US 4389393 A	21-06-1983	AR 230569 A	31-05-1984
		BE 896136 A	01-07-1983
		BR 8300260 A	28-08-1984
		CA 1188614 A	11-06-1985
		CH 655241 A	15-04-1986
		DE 3309516 A	01-12-1983
		DK 137983 A,B,	27-09-1983
		FR 2523845 A	30-09-1983
		GB 2117239 A,B	12-10-1983
		JP 1740831 C	15-03-1993
		JP 4015208 B	17-03-1992
		JP 58174311 A	13-10-1983
		JP 61178916 A	11-08-1986
		NL 8301042 A	17-10-1983
		SE 453797 B	07-03-1988
		SE 8301579 A	27-09-1983
		ZA 8301817 A	28-12-1983
WO 9734932 A	25-09-1997	AU 2036997 A	10-10-1997
US 5000962 A	19-03-1991	NONE	
WO 9737639 A	16-10-1997	CA 2173818 A	11-10-1997
		AU 2283297 A	29-10-1997
		NO 984703 A	08-12-1998
		US 5885615 A	23-03-1999